20% Special Sale Ends Today! Hurry Up!!!

Cervical Cancer in India

Cervical Cancer in India mind map
Recent News
Special Push in Budget 2024
India's First Indigenous HPV Vaccine
Name
Cervavac
Manufacturer
Serum Institute of India
Type
Quadrivalent
Cost
₹4,000 for two doses
₹2,000 per dose
When
Early Vaccination Optimal
Age
9 to 14 years
Why
Prevention of Cervical Cancer
What
Symptoms
Early Stages
Often Asymptomatic
Advanced Stages
Unusual Vaginal Bleeding
Foul-smelling Discharge
Pelvic Pain
HPV Vaccines
Types
Cervarix
Bivalent
Protects Against
HPV Types 16, 18
Gardasil
Quadrivalent
Protects Against
HPV Types 16, 18, 6, 11
Cost
₹3,957 per dose
Cervavac
Quadrivalent
Made in India
Screening Methods
Importance in Prevention
Treatment Services
Accessibility Issues
Where
Urban and Rural India
Urban Trends
Breast Cancer More Common
Rural Trends
High Incidence of Cervical Cancer
Who
Key Figures
Dr. Priya SP Patil
Consultant Obstetrician and Gynaecologist
Dr. Vigyan Mishra
Chief of Lab-Neuberg Diagnostics
Dr. Niti Raizada
Senior Director, Medical Oncology, Fortis Hospitals
How
Vaccination Programs
Government Initiatives
Budget Allocation
Public Health Centre Distribution
Significance
Preventable and Curable Disease
Potential for Cervical Cancer Elimination
Reduction in Other HPV-related Cancers
Challenges
High Vaccine Costs
Accessibility in Rural Areas
Social and Economic Constraints
Way Forward
Achieve 90% Vaccination by 2030
Increase Public Awareness
Enhance Accessibility in Rural Areas

Cervical cancer in India is a critical health concern, currently receiving heightened attention due to the introduction of vaccination initiatives in the 2024 budget. The disease, once predominant among women, especially in rural areas, is now preventable and curable with early detection and vaccination. India has introduced its first indigenous HPV vaccine, Cervavac, developed by the Serum Institute of India. This quadrivalent vaccine is a proactive step towards reducing cervical cancer risk and is most effective when administered to young individuals between 9 to 14 years. Challenges remain in terms of vaccine accessibility and cost, particularly in rural areas. The government’s recent efforts aim to make the vaccine more accessible through public health centres, targeting a 90% vaccination rate by 2030. This approach not only addresses cervical cancer but also other HPV-related cancers, underscoring the significance of early intervention and widespread vaccination programs in India.

Related Posts

Subscribe
Notify of
guest
0 Comments
Inline Feedbacks
View all comments
X
Home Courses Plans Account
20% Special Sale Ends Today! Hurry Up!!!